Friday, July 10, 2026

Drug profile · INN

metharbital

metharbital (GEMONIL) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — metharbital
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

metharbital (GEMONIL) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN metharbital
Brand GEMONIL
Mechanism GABA-A receptor; anion channel positive allosteric modulator
Target GABA-A receptor; anion channel
Route ORAL
Formulation TABLET

Mechanism of action

GABA-A receptor; anion channel positive allosteric modulator

Primary target: GABA-A receptor; anion channel

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. acamprosate calcium GABA-A receptor; anion channel positive modulator
  2. alprazolam GABA-A receptor; anion channel positive allosteric modulator
  3. butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
  4. chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
  5. clobazam GABA-A receptor; anion channel positive allosteric modulator
  6. clonazepam GABA-A receptor; anion channel positive allosteric modulator

Frequently asked questions

What is metharbital?

metharbital (GEMONIL) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for metharbital?

GEMONIL is a marketed brand name for metharbital. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of metharbital?

metharbital has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.